神经红蛋白作为预测动脉瘤性蛛网膜下腔出血不良结局的新型生物标志物
该研究检测58例动脉瘤性蛛网膜下腔出血(aSAH)患者和27例对照者的血清神经红蛋白(Ngb)水平,发现aSAH后第2天Ngb水平与6个月死亡率和不良结局独立相关,提示Ngb可能作为预测aSAH不良结局的新型生物标志物。
要点
- aSAH患者入院时血清Ngb高于对照组(7.67 ± 2.56 ng/mL vs. 6.45 ± 0.88 ng/mL,P < 0.05)。
- aSAH后第2天血清Ngb水平与6个月死亡率独立相关(OR = 0.265,95% CI = 0.094-0.747,P < 0.05)。
- aSAH后第2天血清Ngb水平与6个月不良结局独立相关(OR = 1.919,95% CI = 1.158-3.180,P < 0.05)。
核心结论
- aSAH后第2天血清Ngb水平与aSAH不良结局密切相关,提示Ngb可能作为预测aSAH不良结局的新型生物标志物。
研究设计与样本
- 研究纳入58例aSAH患者和27例对照者,采用酶联免疫吸附法测定血清Ngb水平。
- 在aSAH后第1、2、3、5、7天连续测定血清Ngb水平,并使用Hunt和Hess量表、格拉斯哥昏迷量表(GCS)、世界神经外科医师联盟(WFNS)量表及改良Fisher量表收集临床数据。
- 临床结局包括6个月死亡率和6个月不良结局(改良Rankin量表(mRS)评分3-6分)。
主要发现
- 血清Ngb水平在aSAH后升高,第2天达峰值,随后逐渐下降。
- 入院时血清Ngb水平患者组高于对照组(7.67 ± 2.56 ng/mL vs. 6.45 ± 0.88 ng/mL,P < 0.05)。
- 多因素logistic回归分析显示,aSAH后第2天血清Ngb水平与6个月死亡率独立相关(OR = 0.265,95% CI = 0.094-0.747,P < 0.05)。
- 多因素logistic回归分析显示,aSAH后第2天血清Ngb水平与6个月不良结局独立相关(OR = 1.919,95% CI = 1.158-3.180,P < 0.05)。
- 受试者工作特征曲线分析显示,基于最佳阈值,aSAH后第2天血清Ngb水平预测6个月死亡率和6个月不良结局的曲线下面积分别为0.893(P < 0.05;95% CI,0.812-0.974)和0.818(P < 0.05;95% CI,0.691-0.954)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Neuroglobin (Ngb) has a high affinity for oxygen and helps prevent hypoxic-ischemic brain damage. In this study we analyzed the relationship between Ngb levels and clinical outcomes of aneurysmal subarachnoid hemorrhage (aSAH). METHODS: Serum Ngb levels were measured in 58 patients with aSAH and 27 control individuals using the enzyme-linked immunosorbent assay. To continuously assess aSAH, we measured serum Ngb levels on days 1, 2, 3, 5, and 7 after aSAH. Clinical data were collected using the Hunt and Hess Scale, the Glasgow Coma Scale (GCS), the World Federation of Neurological Surgeons (WFNS) Scale, and the modified Fisher Scale. Clinical outcomes included 6-month mortality and 6-month unfavorable outcomes (modified Rankin Scale (mRS) score of 3-6). RESULTS: Serum Ngb levels increased after aSAH, peaked on day 2, and then gradually decreased. Serum Ngb levels on admission were higher in the patient group than in the control group (7.67 ± 2.56 ng/mL vs. 6.45 ± 0.88 ng/mL, P < 0.05). Multivariate logistic regression analysis indicated that serum Ngb levels on day 2 after aSAH were independently related to 6-month mortality (odds ratio [OR] = 0.265, 95% confidence interval [CI] = 0.094-0.747, P < 0.05) and 6-month unfavorable outcomes (OR = 1.919, 95% CI = 1.158-3.180, P < 0.05), and receiver operating characteristic curve analysis showed that serum Ngb levels on day 2 predicted 6-month mortality and 6-month unfavorable outcomes, with areas under the curve of 0.893 (P < 0.05; 95% CI, 0.812-0.974) and 0.818 (P < 0.05; 95% CI, 0.691-0.954), respectively, based on the best thresholds. CONCLUSIONS: Serum Ngb levels on day 2 after aSAH were strongly associated with poor outcomes in aSAH, suggesting that Ngb may be a novel biomarker for predicting poor outcomes in aSAH.
引用
- Cai H, Zheng S, Cai B, et al. Neuroglobin as a Novel Biomarker for Predicting Poor Outcomes in Aneurysmal Subarachnoid Hemorrhage. World Neurosurg. 2018. PMID: 29738858. doi:10.1016/j.wneu.2018.04.184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。